Business ❯ Pharmaceuticals ❯ Manufacturing

Investment

Eli Lilly AstraZeneca Job Creation Expansion Astrazeneca Sanofi Research and Development Supply chain Tariffs Mexico Merck Domestic Production Supply Boost AbbVie Moderna Canada U.S. Manufacturing Merck & Co Infrastructure Drug Production Novartis

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

The buildout strengthens U.S. supply for high‑demand obesity drugs plus diabetes treatments.

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

UCB Picks Georgia’s Rowen for $2 Billion Biologics Campus

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

AstraZeneca Invests $2 Billion to Expand Maryland Biologics and Build New Clinical Site

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Merck Breaks Ground on $3 Billion Virginia Plant in $70 Billion U.S. Expansion

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites

AbbVie to Build $195 Million API Facility in North Chicago

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030